Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/1/2023 | Buy → Hold | The Benchmark Company | |
2/17/2022 | $8.00 → $7.00 | Overweight | Cantor Fitzgerald |
11/16/2021 | $10.00 → $9.00 | Buy | Aegis Capital |
SC 13G - VOLITIONRX LTD (0000093314) (Subject)
SC 13G - VOLITIONRX LTD (0000093314) (Subject)
SC 13G/A - VOLITIONRX LTD (0000093314) (Subject)
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
Conference call to take place on Monday, March 31 at 4:30 p.m. U.S Eastern Time HENDERSON, Nev., March 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Monday, March 31 at 4.30 p.m. U.S. Eastern Time to discuss its financial and operating results for the fourth quarter and full fiscal year 2024, in addition to providing a business update. Details of this event can be found below. Event: VolitionRx Limited Full Fiscal Year 2024 Earnings and Business Update Conference CallDate: Monday, March 31, 2025Time: 4:30 p.m. U.S. Eastern Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll fre
Conference call to discuss financial and operational results scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev. , Nov. 14, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter of 2024. Volition management will host a conference call tomorrow, November 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Highlights Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 17 countries worldwid
Conference call to take place on Friday, November 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev., Nov. 8, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, November 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the third quarter 2024, in addition to providing a business update. Details of this event can be found below. Event: VolitionRx Limited Third Quarter 2024 Earnings and Business Update Conference Call Date: Friday, November 15, 2024 Time: 8:30 a.m. U.S. Eastern Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll free)Toll/Internati
The Benchmark Company downgraded VolitionRx from Buy to Hold
Cantor Fitzgerald resumed coverage of VolitionRx with a rating of Overweight and set a new price target of $7.00 from $8.00 previously
Aegis Capital reiterated coverage of VolitionRX with a rating of Buy and set a new price target of $9.00 from $10.00 previously
Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time HENDERSON, Nevada, March 31, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the fourth quarter and full fiscal year ended December 31, 2024. Volition management will host a conference call today, March 31 at 4:30 p.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Highlights Sold approximately 120,000 Nu.Q® Vet Cancer Tests in 2024.Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in over
Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and how Volition's Nu.Q® H3.1, low-cost immunoassay may be utilized for the early identification of subjects at high risk of cancer HENDERSON, Nev., March 28, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces two poster presentations at the European Society for Medical Oncology (ESMO)'s European Lung Cancer Congress 2025 (ELCC 2025). The studies demonstrate how Volition's Nu.Q® H3K27Me3 biomarker, when combined with circulating tumor
HENDERSON, Nev., March 27, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces it will host a virtual investor event on Wednesday, April 9, 2025, at 10:00 AM ET, featuring Volition's Gael Forterre, Chief Commercial Officer, Dr. Andrew Retter, Chief Medical Officer and Dr. Jake Micallef, Chief Scientific Officer. To register, click here. This webinar will provide an overview following the completion of a number of large independent studies supporting the value of our Nu.Q® platform in cancer. Mr. Forterre will provide an update on Volition's progress to commercialization through both licensing and direct and indirect sales.
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
HENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year. Volition's major achievements in 2024 include: Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 20 countries worldwide.Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.Hosted Satellite Symposium at European Society of Intensive Care Medicine 2024 showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients.Continued to strengthen our strategic patent portfolio.Made significant progress a
HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his background includes extensive experience in designing and implementing highly focused commercial and business development
HENDERSON, Nev., Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024. Dr. Rubin has also been appointed as a member of the Audit Committee and the Compensation Committee. Dr. Rubin has over 20 years' experience within the life sciences sector, leading healthcare innovation and commercialization strategies for a wide range of organizations – from early-stage operations to large global corporate businesses
10-K - VOLITIONRX LTD (0000093314) (Filer)
8-K - VOLITIONRX LTD (0000093314) (Filer)
8-K - VOLITIONRX LTD (0000093314) (Filer)